Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)
Fatal Adverse Events (FADEs) are a major public health problem, and some FADEs could be preventable. The aim of the present study is to describe the frequency, the drugs involved and the preventability in the FADEs collected through the MEREAFaPS Study between 2012 and 2018. All cases including the outcome "death" have been examined. We excluded cases with vaccine-related ADEs, overdose or suicide, and ADEs occurred during the hospitalisation. Two trained assessors evaluated all cases fulfilling the inclusion criteria. ADEs' preventability was evaluated applying the Schumock and Thornton algorithm. During the study period, we observed 429 cases of death, 92 of which were excluded. The remaining 337 cases involved 187 women and 150 men, with a mean age of 79 and of 77 years, respectively. For each report, the suspected drugs and concomitant ones were 1.26 and 4.20, respectively. Anticoagulants and antiplatelet agents account for more than 40% of FADE cases and the most frequent reactions are haemorrhages (37.5%). The 25% of the FADEs were preventable. This study confirms that FADEs are still a relevant clinical occurrence, and are often caused by widely used old drugs associated with adverse events. The death of one in four patients was preventable. Further efforts should be done to improve the appropriateness of the therapy, especially in older patients who are treated with anticoagulants.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Internal and emergency medicine - 16(2021), 3 vom: 04. Apr., Seite 741-748 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pagani, Silvia [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adverse drug reaction |
|---|
| Anmerkungen: |
Date Completed 15.09.2021 Date Revised 15.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11739-020-02521-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319569705 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319569705 | ||
| 003 | DE-627 | ||
| 005 | 20231225171730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11739-020-02521-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1065.xml |
| 035 | |a (DE-627)NLM319569705 | ||
| 035 | |a (NLM)33392971 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pagani, Silvia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2021 | ||
| 500 | |a Date Revised 15.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Fatal Adverse Events (FADEs) are a major public health problem, and some FADEs could be preventable. The aim of the present study is to describe the frequency, the drugs involved and the preventability in the FADEs collected through the MEREAFaPS Study between 2012 and 2018. All cases including the outcome "death" have been examined. We excluded cases with vaccine-related ADEs, overdose or suicide, and ADEs occurred during the hospitalisation. Two trained assessors evaluated all cases fulfilling the inclusion criteria. ADEs' preventability was evaluated applying the Schumock and Thornton algorithm. During the study period, we observed 429 cases of death, 92 of which were excluded. The remaining 337 cases involved 187 women and 150 men, with a mean age of 79 and of 77 years, respectively. For each report, the suspected drugs and concomitant ones were 1.26 and 4.20, respectively. Anticoagulants and antiplatelet agents account for more than 40% of FADE cases and the most frequent reactions are haemorrhages (37.5%). The 25% of the FADEs were preventable. This study confirms that FADEs are still a relevant clinical occurrence, and are often caused by widely used old drugs associated with adverse events. The death of one in four patients was preventable. Further efforts should be done to improve the appropriateness of the therapy, especially in older patients who are treated with anticoagulants | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Adverse drug reaction | |
| 650 | 4 | |a Appropriateness of drug use | |
| 650 | 4 | |a Drug safety | |
| 650 | 4 | |a Medication error | |
| 650 | 4 | |a Pharmacovigilance | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 700 | 1 | |a Lombardi, Niccolò |e verfasserin |4 aut | |
| 700 | 1 | |a Crescioli, Giada |e verfasserin |4 aut | |
| 700 | 1 | |a Vighi, Giuditta Violetta |e verfasserin |4 aut | |
| 700 | 1 | |a Spada, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Romoli, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Andreetta, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Capuano, Annalisa |e verfasserin |4 aut | |
| 700 | 1 | |a Marrazzo, Eleonora |e verfasserin |4 aut | |
| 700 | 1 | |a Marra, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Leoni, Olivia |e verfasserin |4 aut | |
| 700 | 1 | |a Vannacci, Alfredo |e verfasserin |4 aut | |
| 700 | 1 | |a Venegoni, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Vighi, Giuseppe Danilo |e verfasserin |4 aut | |
| 700 | 0 | |a MEREAFaPS Study group |e verfasserin |4 aut | |
| 700 | 1 | |a Bettiol, Alessandra |e investigator |4 oth | |
| 700 | 1 | |a Bettoni, Daria |e investigator |4 oth | |
| 700 | 1 | |a Blandizzi, Corrado |e investigator |4 oth | |
| 700 | 1 | |a Bonaiuti, Roberto |e investigator |4 oth | |
| 700 | 1 | |a Borsi, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Capuano, Annalisa |e investigator |4 oth | |
| 700 | 1 | |a Cecchi, Errica |e investigator |4 oth | |
| 700 | 1 | |a Convertino, Irma |e investigator |4 oth | |
| 700 | 1 | |a Crescioli, Giada |e investigator |4 oth | |
| 700 | 1 | |a Del Lungo, Martina |e investigator |4 oth | |
| 700 | 1 | |a Di Mauro, Cristina |e investigator |4 oth | |
| 700 | 1 | |a Farina, Gabriella |e investigator |4 oth | |
| 700 | 1 | |a Ferraro, Sara |e investigator |4 oth | |
| 700 | 1 | |a Fucile, Annamaria |e investigator |4 oth | |
| 700 | 1 | |a Galfrascoli, Elena |e investigator |4 oth | |
| 700 | 1 | |a Geninatti, Elisabetta |e investigator |4 oth | |
| 700 | 1 | |a Giovannetti, Linda |e investigator |4 oth | |
| 700 | 1 | |a Leonardi, Luca |e investigator |4 oth | |
| 700 | 1 | |a Liccardo, Rosa |e investigator |4 oth | |
| 700 | 1 | |a Lombardi, Niccolò |e investigator |4 oth | |
| 700 | 1 | |a Marra, Anna |e investigator |4 oth | |
| 700 | 1 | |a Marrazzo, Eleonora |e investigator |4 oth | |
| 700 | 1 | |a Monina, Giovanna |e investigator |4 oth | |
| 700 | 1 | |a Mugelli, Alessandro |e investigator |4 oth | |
| 700 | 1 | |a Pagani, Silvia |e investigator |4 oth | |
| 700 | 1 | |a Parrilli, Maria |e investigator |4 oth | |
| 700 | 1 | |a Rafaniello, Concetta |e investigator |4 oth | |
| 700 | 1 | |a Rossi, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Rossi, Marco |e investigator |4 oth | |
| 700 | 1 | |a Rostan, Stefania |e investigator |4 oth | |
| 700 | 1 | |a Ruocco, Marco |e investigator |4 oth | |
| 700 | 1 | |a Sironi, Marita |e investigator |4 oth | |
| 700 | 1 | |a Spada, Giulia |e investigator |4 oth | |
| 700 | 1 | |a Sportiello, Liberata |e investigator |4 oth | |
| 700 | 1 | |a Tuccori, Marco |e investigator |4 oth | |
| 700 | 1 | |a Vannacci, Alfredo |e investigator |4 oth | |
| 700 | 1 | |a Venegoni, Mauro |e investigator |4 oth | |
| 700 | 1 | |a Vighi, Giuditta Violetta |e investigator |4 oth | |
| 700 | 1 | |a Vighi, Giuseppe Danilo |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Internal and emergency medicine |d 2006 |g 16(2021), 3 vom: 04. Apr., Seite 741-748 |w (DE-627)NLM165086432 |x 1828-0447 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2021 |g number:3 |g day:04 |g month:04 |g pages:741-748 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11739-020-02521-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2021 |e 3 |b 04 |c 04 |h 741-748 | ||